Clinical trial · Interventional
Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5)
Sentinel Lymph Node Assessment In Ovarian Cancer - Turkish Gynecologic Oncology Group Study (TRSGO-SLN-005)
NCT04714931CI-TRIAL-00049996unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study to evaluate the feasibility and accuracy of sentinel lymph node technique in ovarian cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Sentinel Lymph Node | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sentinel lymph node detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Sentinel Lymph Node
- description
- Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
- interventionNames
- Diagnostic Test: Sentinel lymph node detection
Primary outcomes (5)
- measure
- Sentinel lymph node localization
- timeFrame
- 12 months
- description
- Localization areas of pelvic and paraaortic sentinel lymph nodes for ovarian cancer will be identified.
- measure
- Sentinel lymph node technique accuracy in ovarian cancer
- timeFrame
- 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with Early stage ovarian cancer Exclusion Criteria: * Patient who had been administrated chemotherapy prior to surgery * Patients who had diagnosed with malignancy other than ovarian cancer. * Patients who had undergone pelvic or paraaortic lymphadenectomy or surgery prior to surgery. * Patients who have allergy for the tracers.
References
Publications (0)
Data not yet available
No reference posted for this study.